New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment ...Middle East

STOCKHOLM, Dec. 4, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's Disease (CTAD) conference, held in San Diego...

Hence then, the article about new leqembi data presented at ctad 2025 suggests potential to delay disease progression by up to 8 3 years with continued treatment was published today ( Thursday 04/12/2025 - 10:17 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment )

Also on site :

• KLOS-FM host Uncle Joe Benson, one LA radio’s legendary voices, dies at 76
• Fitness Influencer Lee ‘Malibu’ Markham Admits He Falsely Claimed IED Injury
• OpenAI says Canada mass shooter evaded ban with second ChatGPT account